Skip to main content
Frontiers in Oncology logoLink to Frontiers in Oncology
. 2023 Dec 15;13:1302413. doi: 10.3389/fonc.2023.1302413

Corrigendum: Targeting thymidylate synthase enhances the chemosensitivity of triple-negative breast cancer towards 5-FU-based combinatorial therapy

Nair Hariprasad Haritha 1, Akbar Nawab 2,, Vinod Vijayakurup 2,, Nikhil Ponnoor Anto 3, Vijayasteltar B Liju 1, Vijai V Alex 1, Areekkara Nisthul Amrutha 4, Sreekumar U Aiswarya 5, Mundanattu Swetha 1, Balachandran S Vinod 1, Sankar Sundaram 6, Maria V Guijarro 2, Thomas Herlevich 2, Archana Krishna 1, Nesteena K Nestory 1, Smitha V Bava 5, Chittalakkottu Sadasivan 4, Maria Zajac-Kaye 2, Ruby John Anto 1,*
PMCID: PMC10755737  PMID: 38162481

In the published article, there was an error in Figure 5A (i) and Figure 5D (ii) as published. The image of excised tumor of animal treated with curcumin that is present in Figure 2A was wrongly placed as image of excised tumor in the control group in Figure 5A (i). In Figure 5D (ii), an error happened during the cropping and placing of the IHC images. The IHC image depicting the expression status of TS in curcumin-treated tumor samples of MDA-MB-231 TS-ve panel was accidentally duplicated and the same image was placed as IHC image depicting the expression status of p-p65 in curcumin-treated tumor samples of MDA-MB-231 TS-ve panel. We have rectified this mistake in the revised Figure 5 and the duplicated images have been replaced by the correct ones. The corrected Figure 5 and its caption appear below.

Figure 5.

Figure 5

The role of TS in regulating the synergism of 5-FU and curcumin. [A (i, ii)] Representative images of animals from each experimental group, bearing tumor produced by orthotopic injection of both sets of transduced cells and tumors excised showed a reduction in tumor size upon completion of treatment. (B, C) Graphs showing a comparison of tumor volume of MDA-MB-231TS and MDA-MB-231TS- xenografts, respectively upon completion of treatment. Significant reduction in tumor volume is observed in animals bearing MDA-MB-231TS xenografts, upon treatment with combination while no significant reduction in tumor volume is observed in animals bearing MDA-MB-231TS- xenografts. Data represent two independent sets of experiments and results are shown as the mean ± S.D. P-values were calculated with one-way ANOVA. ***P-values ≤0.001, **P-values ≤0.01 and *P-values ≤0.05; ns represents non-significance. [D (i, ii)] Immunohistochemical analysis of expression status of TS and p65 sub-unit of NF-κB in different treatment groups of MDA-MB-231TS and MDA-MB-231TS- xenografts, respectively.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA

RESOURCES